Financial Performance - CRISPR Therapeutics reported a fourth-quarter 2025 loss of $1.37 per share, which was wider than the Zacks Consensus Estimate of a loss of $1.15, compared to a loss of 44 cents per share in the same quarter last year [1] - Total revenues for the quarter were $0.9 million, significantly missing the Zacks Consensus Estimate of $4.0 million, and down from $35.7 million in the year-ago period, which included $35 million in collaboration revenues from Vertex Pharmaceuticals [2] - Research and development (R&D) expenses increased by 16% year over year to $83.5 million, while general and administrative expenses rose about 2% to $18.4 million [8] Stock Performance - Shares of CRISPR Therapeutics declined in after-market trading due to the wider-than-expected loss, with the stock rising nearly 13% over the past year compared to the industry's 19% growth [3] Product Development and Sales - CRISPR Therapeutics and Vertex Pharmaceuticals' gene therapy, Casgevy, is approved in the U.S. and Europe for sickle cell disease and transfusion-dependent beta thalassemia, with Vertex leading global development and commercialization [5] - Vertex reported Casgevy sales of $54 million in the fourth quarter, up from $16.9 million in the previous quarter, contributing to full-year 2025 sales of $116 million [6] - The company plans to file for label expansions for Casgevy in patients aged five to 11 years in the first half of 2026, utilizing the Commissioner's National Priority Voucher to expedite the FDA review process [11] Pipeline Updates - CRISPR Therapeutics is advancing CAR-T cell therapies, with updates on the candidate zugo-cel expected in the second half of 2026 [12] - The company is also focusing on in-vivo candidates, particularly CTX310 for severe hypertriglyceridemia and refractory hypercholesterolemia, with updates anticipated in the second half of 2026 [13] - A collaboration with Sirius Therapeutics is diversifying the pipeline into RNA therapeutics, with an investigational RNA therapy CTX611 in mid-stage studies for preventing venous thromboembolism, with top-line data expected in the second half of 2026 [14] Financial Position - As of December 31, 2025, CRISPR Therapeutics had cash, cash equivalents, and marketable securities worth $1.98 billion, an increase from $1.94 billion as of September 30, 2025, primarily due to proceeds from common share issuance [10]

Core Insights - CRISPR Therapeutics reported financial results for Q4 and full year 2025, highlighting progress in its clinical and preclinical pipeline, including advancements in autoimmune diseases and oncology, as well as the global uptake of its therapy CASGEVY [1][2] Financial Performance - CASGEVY generated Q4 2025 revenue of $54 million and full year revenue of $116 million, with a significant increase in patient initiations and first cell collections, nearly tripling from 2024 to 2025 [5] - Cash, cash equivalents, and marketable securities totaled $1,975.8 million as of December 31, 2025, up from $1,903.8 million in 2024, primarily due to common share issuance and interest income [14] - R&D expenses for Q4 2025 were $83.5 million, an increase from $71.7 million in Q4 2024, driven by higher licensing fees [14] - The net loss for Q4 2025 was $130.6 million, compared to a net loss of $37.3 million in Q4 2024 [14] Pipeline Developments - The company is advancing its in vivo liver editing portfolio and has made progress with its siRNA collaboration with Sirius Therapeutics [2][4] - CTX310, targeting ANGPTL3, is in Phase 1b trials for severe hypertriglyceridemia and refractory hypercholesterolemia, with updates expected in H2 2026 [5] - CTX460, targeting SERPINA1 for alpha-1 antitrypsin deficiency, is expected to enter clinical trials in mid-2026 [5] - Zugo-cel is in ongoing Phase 1 trials for autoimmune diseases and hematologic malignancies, with updates anticipated in H2 2026 [10][17] Market Expansion - CASGEVY is approved in multiple regions, including the U.S., EU, and several Middle Eastern countries, with approximately 90% of U.S. patients having reimbursed access [5] - The company is expanding its regenerative medicine portfolio, including CTX213 for Type 1 diabetes, which has shown promising preclinical efficacy [9] Collaborations - CRISPR Therapeutics has a strategic collaboration with Vertex Pharmaceuticals for CASGEVY, with Vertex leading global development and commercialization [13] - The collaboration with Sirius Therapeutics focuses on developing siRNA therapies, with CTX611 being a key program targeting FXI for thromboembolic disorders [19]

Summary of CRISPR Therapeutics FY Conference Call Company Overview - **Company**: CRISPR Therapeutics (NasdaqGM:CRSP) - **Event**: FY Conference Call on January 12, 2026 - **Focus**: Progress and updates on gene editing technologies and therapies Key Points Industry and Market Position - CRISPR Therapeutics is focused on transforming medicine through gene editing, aiming to develop cures for serious diseases [2][34] - The company has made significant advancements across four franchises, including hemoglobinopathies, in vivo gene editing, CAR-T therapies, and RNA-based therapies [2][3] Hemoglobinopathies - **Casgevy**: An approved product with multi-billion dollar revenue potential, showing a 3x increase in patient initiation and cell collections from 2024 to 2025 [5][6] - Revenue surpassed $100 million, with positive payer coverage in the U.S. and Europe [5][6] - Pediatric data for sickle cell and thalassemia shows promising results, expanding the addressable patient population [6][7] In Vivo Gene Editing - Focus on in vivo gene editing of the liver, with promising data for CTX310 targeting hypercholesterolemia [3][11] - A single infusion can lead to a nearly 50% reduction in LDL cholesterol and a 55% reduction in triglycerides [14][15] - The potential for a multi-billion dollar opportunity in treating cardiovascular diseases [17] CAR-T Therapies - CTX112 shows a 70% complete response rate in oncology settings, with a favorable safety profile [27][28] - The company is exploring maintenance therapies to enhance durability of responses [28] - In vivo CAR-T approaches are being developed, utilizing proprietary lipid nanoparticle systems [30] RNA-Based Therapies - CTX611 targets Factor XI, with a potential to revolutionize anticoagulation therapy, showing a 93% reduction in Factor XI antigen levels [21][23] - The siRNA market is projected to be a $20 billion opportunity, with CRISPR's approach aiming to reduce bleeding risks associated with current therapies [21][24] Regulatory and Future Outlook - The FDA is supportive of gene editing technologies, which may facilitate smoother regulatory pathways for CRISPR's programs [40][41] - The company anticipates pivotal trials for several programs, including A1AT and CTX310, in the coming years [36][39] - Continuous innovation and partnerships are expected to enhance the development of their pipeline [47][48] Financial Considerations - CRISPR aims to reduce healthcare costs through one-time gene editing solutions, potentially pricing therapies below $100,000 [50] - The company is focused on creating pharmacoeconomic benefits through its innovative therapies [50] Societal Impact and Diversity - The company acknowledges the importance of addressing racial and ethnic differences in treatment responses, particularly in hypertension medications [51] AI Integration - AI is being utilized to enhance efficiency in clinical trials and improve gene editing processes, particularly in protein and mRNA design [53] Conclusion - CRISPR Therapeutics is positioned for significant growth with a diverse pipeline of innovative therapies across multiple disease areas, supported by strong market potential and favorable regulatory conditions. The company is committed to continuous innovation and addressing healthcare affordability through its gene editing technologies [34][56]

Core Insights - CRISPR Therapeutics is set for a significant year in 2026, with multiple data releases and milestones anticipated across its portfolio [1][2] - The company is focusing on the acceleration of CASGEVY, which has multi-billion-dollar potential, alongside a diverse pipeline supported by advanced gene-editing technologies [1][2] Financial Position - The company starts 2026 with a robust balance sheet, holding approximately $2 billion in cash, cash equivalents, and marketable securities [1] Product Pipeline and Milestones - CASGEVY is expected to see continued global commercialization, with regulatory submissions for patients aged 5-11 anticipated in the first half of 2026 [4][8] - Updates on CTX310 and the Lp(a) program are expected in the second half of 2026, with CTX611's Phase 2 clinical data also anticipated during this period [4][8] - The company plans to initiate clinical trials for CTX460 in alpha-1 antitrypsin deficiency and CTX340 in refractory hypertension in mid-2026 and the first half of 2026, respectively [4][8] CASGEVY Overview - CASGEVY is a CRISPR/Cas9 gene-edited cell therapy approved for patients with sickle cell disease and transfusion-dependent beta thalassemia, showing significant revenue growth exceeding $100 million in 2025 [10][4] - The therapy has demonstrated a nearly three-fold increase in patient initiations and first cell collections in 2025 compared to 2024 [4] In Vivo and siRNA Programs - The company is advancing a diversified portfolio of in vivo gene editing programs utilizing its proprietary lipid nanoparticle (LNP) delivery platform [5][12] - The siRNA-based portfolio includes clinical-stage programs targeting cardiovascular and thromboembolic diseases, developed in collaboration with Sirius Therapeutics [6][17] Autoimmune Disease and Oncology - Zugocabtagene geleucel (zugo-cel) is progressing in clinical trials for autoimmune diseases and hematologic malignancies, with updates expected in the second half of 2026 [7][14] - The company has established collaborations to expand the development of zugo-cel in aggressive B-cell lymphomas [14][17]

Core Insights - CRISPR Therapeutics has reported strong progress across its portfolio, particularly with CASGEVY® and CTX310®, indicating a robust pipeline and potential for significant revenue growth in the coming years [2][3] CASGEVY® Developments - CASGEVY® is a CRISPR/Cas9 gene-edited cell therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), approved in multiple regions including the U.S. and Europe [3][13] - Nearly 300 patients have been referred to Authorized Treatment Centers (ATCs), with approximately 165 completing their first cell collection and 39 receiving infusions [5][3] - The company anticipates over $100 million in total CASGEVY revenue for this year, with significant growth expected in 2026 [5][3] Clinical Trials and Pipeline - Positive Phase 1 data for CTX310®, targeting ANGPTL3, was presented at the AHA Scientific Sessions, showing potential to lower triglycerides and LDL [5][3] - Enrollment in two global Phase 3 studies for pediatric development of exa-cel has been completed, with initial data to be presented at the ASH annual meeting [5][3] - Ongoing clinical trials for CTX112™, targeting CD19, are expected to provide broad updates by year-end [5][10] Financial Performance - As of September 30, 2025, the company reported approximately $1.9 billion in cash, cash equivalents, and marketable securities [5][12] - R&D expenses decreased to $58.9 million for Q3 2025 from $82.2 million in Q3 2024, indicating improved cost management [12][26] - The net loss for Q3 2025 was $106.4 million, compared to a net loss of $85.9 million in Q3 2024, reflecting ongoing investment in R&D [12][26] Innovative Technologies - The company is advancing its proprietary SyNTase™ editing platform, which aims to enable precise in vivo gene correction, with CTX460™ expected to enter clinical trials in mid-2026 [5][3] - CTX340™, targeting AGT for refractory hypertension, has shown promising preclinical results, including significant liver editing and blood pressure reduction [6][5] Strategic Collaborations - CRISPR Therapeutics has a strategic collaboration with Vertex Pharmaceuticals for the development of CASGEVY, sharing program costs and profits [14][3] - A partnership with Sirius Therapeutics is focused on developing SRSD107, a long-acting siRNA targeting Factor XI for thromboembolic disorders [19][18]

Core Insights - CRISPR Therapeutics (CRSP) and Sirius Therapeutics have initiated a phase II study for SRSD107, a long-acting siRNA therapy targeting thromboembolic disorders [1][7] - The study focuses on the prevention of venous thromboembolism (VTE) in patients undergoing total knee arthroplasty (TKA) [2] - CRISPR Therapeutics has seen a 57.7% increase in share price year-to-date, significantly outperforming the industry average of 3.5% [2] Collaboration and Pipeline Expansion - In May 2025, CRISPR Therapeutics entered a collaboration with Sirius Therapeutics to develop and commercialize siRNA therapies, sharing costs and profits equally [4][5] - The collaboration allows CRISPR to exclusively license up to two siRNA programs and retain rights for clinical development and commercialization [5] - This partnership diversifies CRISPR's pipeline into RNA therapeutics, expanding beyond its traditional gene therapies [8] Potential of SRSD107 - If successful, SRSD107 could become a best-in-class therapy for patients at risk of life-threatening thromboembolic events due to co-morbid conditions [6] Casgevy Sales and Future Prospects - CRISPR's gene therapy, Casgevy, approved for sickle cell disease and transfusion-dependent beta-thalassemia, is gaining sales momentum, with $30.4 million recorded in Q2 2025 [9][10] - The company is advancing multiple next-generation gene-edited cell therapy programs, including CAR T candidates for various cancers and autoimmune diseases [10]

Core Insights - CRISPR Therapeutics and Sirius Therapeutics have initiated a Phase 2 clinical trial for SRSD107, a long-acting Factor XI siRNA aimed at preventing venous thromboembolism in patients undergoing total knee arthroplasty [1][2] Company Overview - CRISPR Therapeutics is focused on developing gene-based medicines for serious diseases and has a diverse portfolio that includes CRISPR/Cas9 gene editing therapies [8] - Sirius Therapeutics is a clinical-stage biotech company developing innovative siRNA therapies, with a pipeline targeting coagulation disorders and other chronic diseases [10][11] Clinical Trial Details - The Phase 2 trial is a randomized, multicenter, global study assessing the safety and efficacy of SRSD107 for VTE prevention in TKA patients [2] - SRSD107 aims to selectively inhibit FXI, a key factor in pathological thrombosis, while minimizing effects on normal hemostasis [3] Previous Trial Results - In Phase 1 trials, SRSD107 demonstrated strong pharmacodynamic effects, achieving over 93% reduction in FXI levels and more than twofold increase in activated partial thromboplastin time [3] Collaboration Insights - The strategic collaboration between CRISPR Therapeutics and Sirius Therapeutics was established in 2025 to co-develop siRNA therapies, sharing costs and profits equally [6][7] - CRISPR Therapeutics will lead commercialization efforts in the U.S., while Sirius will focus on Greater China [6] Market Potential - The addressable population for SRSD107 includes patients with various conditions such as atrial fibrillation, VTE, and chronic coronary artery disease, where existing therapies have limitations due to bleeding risks [3]

Core Insights - CRISPR Therapeutics reported a second-quarter 2025 loss of $2.40 per share, wider than the previous year's loss of $1.49, primarily due to a $96.3 million expense related to a collaboration with Sirius Therapeutics [1][6] - Adjusted loss, excluding special items, was $1.29 per share, better than the Zacks Consensus Estimate of a loss of $1.47 [2] - Total revenues for the quarter were $0.89 million, significantly below the Zacks Consensus Estimate of $6.6 million, compared to $0.5 million in the same period last year [2] Financial Performance - CRISPR Therapeutics' stock fell over 8% in after-market trading following the wider-than-expected loss, continuing the downward trend in pre-market trading [3] - The stock has increased by 51% year-to-date, outperforming the industry growth of 2% [3] - Research and development expenses decreased by 13% year-over-year to $69.9 million, while general and administrative expenses fell by 3% to $18.9 million [8] Product Development and Sales - Casgevy, a CRISPR/Cas9 gene-edited therapy developed in partnership with Vertex Pharmaceuticals, saw sales of $30.4 million in Q2, up from $14.2 million in the previous quarter [5][6] - Over 75 treatment centers have been activated globally for Casgevy, with approximately 115 patients completing their first cell collection since its launch [6][7] - The company is advancing its CAR-T and in-vivo therapy pipelines, with updates expected later this year [10][11] Pipeline Expansion - CRISPR Therapeutics is developing two next-generation CAR-T therapy candidates, CTX112 and CTX131, currently in phase I/II studies [10] - The company is also studying in-vivo candidates CTX310 and CTX320, with promising early data showing significant reductions in LDL and triglyceride levels [11] - A collaboration with Sirius Therapeutics has diversified the pipeline into RNA therapeutics, with a focus on the investigational siRNA candidate SRSD107 [12][13] Financial Position - As of June 30, 2025, CRISPR Therapeutics had cash and marketable securities totaling $1.72 billion, down from $1.86 billion at the end of March 2025 [9]

Core Insights - CRISPR Therapeutics is experiencing significant momentum in both commercial and clinical programs, particularly with the activation of over 75 authorized treatment centers for CASGEVY, which has led to approximately 115 patients having cells collected globally [1][2][3] - The company is advancing multiple clinical trials, including CTX310 targeting ANGPTL3, which has shown promising preliminary data with reductions of up to 82% in triglycerides and 86% in LDL [1][3][7] - CRISPR Therapeutics has a strong financial position with approximately $1.7 billion in cash and marketable securities as of June 30, 2025, despite a net loss of $208.5 million for the second quarter of 2025 [1][14][29] Commercial Programs - CASGEVY, a CRISPR/Cas9 gene-edited cell therapy, is approved in multiple regions including the U.S., EU, and Canada for treating sickle cell disease and transfusion-dependent beta thalassemia [3][12] - The company has achieved its target of activating 75 authorized treatment centers globally, with 29 patients having received infusions of CASGEVY, including 16 in the second quarter of 2025 [1][3] - Reimbursement agreements have been secured in 10 countries, enhancing patient access to CASGEVY [3] Clinical Trials - Ongoing clinical trials for CTX310™ are expected to present complete Phase 1 data in the second half of 2025, with preliminary results indicating significant reductions in triglycerides and LDL [1][3][7] - CTX320™ is in a Phase 1 trial targeting the LPA gene, with updates anticipated in the first half of 2026 [1][3] - CTX112™ and CTX131™ are also in clinical trials targeting CD19 and CD70, respectively, with broad updates expected in the second half of 2025 [1][3][7] Financial Performance - For the second quarter of 2025, CRISPR Therapeutics reported a net loss of $208.5 million, compared to a net loss of $126.4 million in the same period of 2024 [14][29] - Research and development expenses decreased to $69.9 million from $80.2 million year-over-year, primarily due to reduced employee-related costs [14][29] - The total operating expenses for the second quarter were $230.2 million, up from $151.8 million in the previous year, largely due to acquired in-process R&D expenses related to the Sirius Agreement [14][29] Strategic Collaborations - A strategic collaboration with Sirius Therapeutics was established to develop and commercialize small interfering RNA (siRNA) therapies, starting with SRSD107 for thromboembolic disorders [13][20] - The European Medicines Agency has authorized a Phase 2 clinical trial for SRSD107, which aims to evaluate its safety and efficacy in preventing postoperative venous thromboembolism [13][20]

Summary of Key Points from the Conference Call Company Overview - CRISPR Therapeutics has been operational for approximately eleven years, with a focus on developing gene editing therapies, particularly in the areas of cardiovascular medicine and autoimmune diseases [1][2] Core Products and Pipeline - **KASJEVY**: Approved for sickle cell disease and thalassemia, currently ramping up commercial uptake with over 65 authorized treatment centers activated globally [2][8] - **Cardiovascular Medicine**: Focus on gene editing therapies targeting ANGPTL3, showing nearly 80% reduction in LDL and triglycerides from a single injection [2][3][20] - **Autoimmune Diseases**: Development of allogeneic CAR T therapies, with plans to expand indications beyond lupus [3][4] Key Data and Results - **ANGPTL3 Targeting**: Initial data indicates a significant reduction in triglycerides and LDL, outperforming expectations and existing therapies [20][21] - **Gentler Preconditioning Regimens**: Development of gentler conditioning methods could expand the addressable market for KASJEVY by 3-4 times [15][17] Market Dynamics - The launch of KASJEVY is compared to medical devices rather than traditional pharmaceuticals, indicating a unique commercialization strategy [10][11] - The cardiovascular space is evolving with multiple modalities, including siRNA and gene editing, with a focus on long-term patient outcomes and compliance [30][35] Competitive Landscape - The company believes that gene editing will provide a superior long-term solution compared to ongoing treatments like siRNA, which require continuous administration [34][36] - The potential for significant cost savings and improved patient compliance with a one-time gene editing therapy versus ongoing treatments [35][36] Future Expectations - Upcoming data releases are anticipated to further validate the efficacy of ANGPTL3 and Lp targeting therapies, with a focus on biomarker-based approvals rather than traditional outcome studies [24][37] - The company is exploring strategic partnerships, particularly in the cardiovascular and autoimmune spaces, as interest in cell and gene therapies increases [52][53] Additional Insights - The company is also working on regenerative medicine for type one diabetes, with ongoing trials for both encapsulated and unencapsulated islet cells [51] - The allogeneic CAR T platform is being optimized, with promising data expected mid-year [45][48] This summary encapsulates the critical aspects of CRISPR Therapeutics' current status, product pipeline, market positioning, and future outlook based on the conference call.